<DOC>
	<DOCNO>NCT00072605</DOCNO>
	<brief_summary>This study test safety experimental vaccine develop protect Ebola virus infection determine vaccine induces immune response virus . The Ebola virus cause disease call Ebola hemorrhagic fever . Symptoms begin fever muscle ache progress breathe problem , severe bleeding , kidney problem , shock . The infection may mild , also lead death . The vaccine use study make small part Ebola genetic material . It cause Ebola hemorrhagic fever develop receive . Healthy volunteer 18 44 year age may eligible study . Candidates screen medical history , physical examination , laboratory test , complete `` assessment understanding '' questionnaire show understand study . Depending order entry study , participant assign receive one three vaccine dose placebo . The first group receive low dose ( 2 milligram ) vaccine placebo . If dose safe , second group receive 4 mg , dose safe , third group receive 8 mg. Injections give muscle upper arm . Participants receive three injection , 4 week apart ( study day 0 , 28 , 56 ) . Participants record temperature symptom diary card 7 day follow injection . They return clinic 2 3 day injection 2 week injection study week 10 . Additional follow-up visit schedule week 12 , 24 , 38 , 52 . At visit , participant provide blood urine sample test vital sign , lymph node check , weight measure , symptom review . Additional laboratory test may request visit .</brief_summary>
	<brief_title>Experimental Ebola Vaccine Trial</brief_title>
	<detailed_description>This Phase I , randomize , placebo-controlled , dose-escalation study Ebola DNA plasmid vaccine . The hypothesis vaccine safe human administration elicit immune response Ebola . Primary objective evaluate safety tolerability investigational vaccine secondary objective evaluate immune response . Randomization assignment blind subject , clinical investigator laboratory investigator .</detailed_description>
	<mesh_term>Hemorrhagic Fevers , Viral</mesh_term>
	<mesh_term>Hemorrhagic Fever , Ebola</mesh_term>
	<criteria>INCLUSION CRITERIA : A volunteer must meet follow inclusion criterion : 1 . 18 44 year old . 2 . Available followup duration study ( 12 month ) . 3 . Able provide proof identity acceptance study clinician complete enrollment process . 4 . Completion Assessment Understanding prior enrollment verbalize understanding question answer incorrectly . 5 . Able willing complete inform consent process . 6 . Willing receive HIV test result willing abide NIH guideline partner notification positive HIV result . 7 . Willing donate blood sample storage . 8 . In good general health without clinically significant medical history . 9 . Physical examination laboratory result without clinically significant finding within 28 day prior enrollment . Laboratory Criteria within 28 day prior enrollment : 10 . Hematocrit equal 34 % woman ; 38 % men . 11 . Normal fibrinogen level , Ddimer immunoassay less 2.0 microg/mL , RBC morphology without evidence microangiopathic hemolysis . 12 . WBC count : NonAfrican Americans : equal 3,30012,000 cells/mm3 , AfricanAmericans : equal 2,500 12,000 cells/mm3 ( absence clinical pathological etiology ) . 13 . Differential either within institutional normal range accompany site physician approval . 14 . Total lymphocyte count : NonAfrican Americans : equal 800 cells/mm3 , African Americans : equal 650 cells/mm3 ( absence clinical pathological etiology ) 15 . Platelets within institutional normal limit . 16 . Prothrombin time activate partial thromboplastin time ( PT , PTT ) within institutional normal range . 17 . Alanine aminotransferase ( ALT ) ( also call SGPT ) = upper limit normal range 18 . Serum creatinine = upper limit normal range 19 . Negative Food Drug Administration ( FDA ) approve HIV blood test 20 . Negative hepatitis B surface antigen ( HbsAg ) 21 . Negative antibody hepatitis C virus ( antiHCV ) , negative HCV PCR antiHCV positive . 22 . Normal urinalysis define negative glucose , negative trace protein , negative hemoglobin dipstick . FemaleSpecific Criteria : 23 . Negative pregnancy test ( urine serum ) woman presume reproductive potential . 24 . A female participant must meet one follow criterion : No reproductive potential menopause ( one year without menses ) hysterectomy , bilateral oophorectomy , tubal ligation , Participant agree heterosexually inactive least 21 day prior enrollment throughout duration study , Participant agree consistently practice contraception least 21 day prior enrollment throughout duration study one follow method : condom , male female , without spermicide diaphragm cervical cap spermicide intrauterine device contraceptive pill patch , Norplant , DepoProvera FDAapproved contraceptive method male partner previously undergone vasectomy documentation EXCLUSION CRITERIA : A volunteer exclude one follow condition apply . Women : 1 . Breastfeeding . Volunteer receive following substance : 2 . Immunosuppressive cytotoxic medication within past six month exception corticosteroid nasal spray allergic rhinitis topical corticosteroid acute uncomplicated dermatitis 3 . Blood product within 120 day prior HIV screen . 4 . Immunoglobulin within 60 day prior HIV screen . 5 . Live attenuate vaccine within 30 day prior initial study injection . 6 . Investigational research agent within 30 day prior initial study injection . 7 . Medically indicated subunit kill vaccine , e.g . influenza , pneumococcal , allergy treatment antigen injection , within 14 day prior initial study injection . 8 . Current antiTB prophylaxis therapy . Volunteer history follow clinically significant condition : 9 . Serious adverse reaction vaccine , anaphylaxis , hive , respiratory difficulty , angioedema , abdominal pain . 10 . Autoimmune disease immunodeficiency . 11 . Asthma unstable require emergent care , urgent care , hospitalization intubation past two year require use oral intravenous corticosteroid . 12 . Diabetes mellitus ( type I II ) , exception gestational diabetes . 13 . Thyroid disease include history thyroidectomy diagnose require medication within past 12 month . 14 . Serious angioedema episode within previous 3 year require medication previous two year . 15 . Hypertension well control medication 145/95 enrollment . 16 . Bleeding disorder diagnose doctor ( e.g . factor deficiency , coagulopathy , platelet disorder require special precaution ) significant bruise bleed difficulty IM injection blood draw . 17 . Malignancy active treat malignancy reasonable assurance sustain cure malignancy likely recur period study . 18 . Seizure disorder : 1 ) febrile seizure age two , 2 ) seizure secondary alcohol withdrawal 3 year ago , 3 ) singular seizure require treatment within last 3 year . 19 . Asplenia condition result absence removal spleen . 20 . Psychiatric condition precludes compliance protocol ; past present psychosis ; past present bipolar disorder require therapy well control medication past two year ; disorder require lithium ; suicidal ideation occur within five year prior enrollment 21 . Any medical , psychiatric , social condition , occupational responsibility , judgment investigator , would interfere serve contraindication protocol adherence volunteer 's ability give inform consent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>44 Years</maximum_age>
	<verification_date>August 22, 2007</verification_date>
	<keyword>Healthy</keyword>
	<keyword>T Cells</keyword>
	<keyword>Immunity</keyword>
	<keyword>Hemorrhagic Fever</keyword>
	<keyword>Healthy Volunteer</keyword>
	<keyword>HV</keyword>
</DOC>